The global biologics safety testing market was valued at USD 3,589.5 million in 2022, which is expected to reach USD 9,370.3 million by 2030, growing at a CAGR of 12.7% during 2022–2030.
 |
| To learn more about this report: https://bit.ly/3pzynnm |
In healthcare, biologics like cell therapies, vaccines, and monoclonal antibodies are becoming increasingly crucial. Comprehensive safety testing is required to assure the quality, efficacy, and safety of biologics as they are a new area of therapeutics that could be toxic for certain patients.
Globally, the biopharmaceutical sector is expanding significantly. The market for biologics safety testing is growing as a result of pharmaceutical companies developing and selling novel biologics.
Biologics safety testing has become more effective and accurate due to the developments in analytical methods including high-throughput screening, PCR, and next-generation sequencing. The market is driven by these technical developments because they allow for quicker and more-thorough safety checks.
North America dominates the biologics safety testing market. The healthcare system in North America is well-established and sophisticated, with advanced research facilities, specialized labs, and an encouraging regulatory framework. The region has become a center for biopharmaceutical research and innovation due to its infrastructure, which facilitates the creation and testing of biologics.
The market for consumables is quite competitive, with a wide variety of items being offered by multiple vendors and manufacturers. This competition encourages innovation, which results in the creation of better consumables that increase the effectiveness and precision of safety testing. The market is driven by the improvements in analytical techniques, the expansion of the biopharmaceutical sector, and the rising demand for biologics.
In the coming years, APAC will grow the fastest in the market, with an over 15% CAGR, on account of its increasing disease-ridden population. Moreover, the advancing healthcare system of regional countries is opening up doors for the providers of biologics, which, in turn, is driving the demand for their safety testing. Additionally, APAC is becoming a preferred destination for CDMO activities, including the safety testing of biologics.
